Treatment of Locally Advanced Non–Small Cell Lung Cancer

Publication date: February 2017
Source:Hematology/Oncology Clinics of North America, Volume 31, Issue 1
Author(s): Kit Tam, Megan Daly, Karen Kelly

Teaser

Locally advanced non–small cell lung cancer is a heterogeneous disease with typically poor outcomes. Select patients may benefit from the integration of surgery, whereas patients with bulky, multistation, or contralateral (N3) mediastinal involvement are managed with definitive chemoradiation. Attempts to improve outcomes through induction, consolidation, or maintenance chemotherapy or radiation dose escalation have not demonstrated a survival benefit. Current research efforts focus on the integration of novel systemic agents that exploit tumor-specific driver mutations, augment antitumor immune response, or enhance radiation sensitivity.


http://ift.tt/2fDv0qh